WEKO3
アイテム
A brief history of drug development for patients with schizophrenia: toward improving their potential in rehabilitation
https://doi.org/10.69202/0000000375
https://doi.org/10.69202/0000000375e54e5959-5fe0-4246-9efe-1419d5810f69
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
C 3-52-58 (890.5 kB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||||
|---|---|---|---|---|---|---|---|---|
| 公開日 | 2022-12-22 | |||||||
| タイトル | ||||||||
| タイトル | A brief history of drug development for patients with schizophrenia: toward improving their potential in rehabilitation | |||||||
| 言語 | en | |||||||
| キーワード | ||||||||
| 主題Scheme | Other | |||||||
| 主題 | antipsychotic drugs | |||||||
| キーワード | ||||||||
| 主題Scheme | Other | |||||||
| 主題 | extrapyramidal symptoms | |||||||
| キーワード | ||||||||
| 主題Scheme | Other | |||||||
| 主題 | drug-induced weight gain | |||||||
| キーワード | ||||||||
| 主題Scheme | Other | |||||||
| 主題 | cognitive function | |||||||
| 資源タイプ | ||||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_1843 | |||||||
| 資源タイプ | other | |||||||
| ID登録 | ||||||||
| ID登録 | 10.69202/0000000375 | |||||||
| ID登録タイプ | JaLC | |||||||
| 内容種別 | ||||||||
| 内容記述タイプ | Other | |||||||
| 内容記述 | REVIEW ARTICLE | |||||||
| 著者 |
Winston W. SHEN
× Winston W. SHEN
|
|||||||
| 抄録 | ||||||||
| 内容記述タイプ | Abstract | |||||||
| 内容記述 | Background: Schizophrenia is one of the most disabling diseases with remarkable functional loss. Drug treatment is still the mainstay in managing patients with schizophrenia. In this article, the author intends to briefly recount a history of the drug development in the treatment for the patients with schizophrenia, and to suggest short list of most suitable drugs for them. Methods: The author comprehensively reviewed the benefits and side effects of all available drugs for treating patients with schizophrenia. Focuses are on drugs with least potential of producing liability of extra-pyramidal symptoms (EPS), and those with mild side effect of weight gain. Results: The drugs for treating patients with schizophrenia were originally targeting at improving positive symptoms of schizophrenia. Those dopamine antagonists (such as chlorpromazine, haloperidol, etc.) improve disorganized behaviors, hallucinations, delusion, and looseness of association effectively but produce unbearable EPS. Recent drugs (mixed receptor antagonists, serotonin-dopamine antagonists, patial dopamine and serotonin agonists) can improve positive, negative symptoms with least EPS but produce body weight gain and other metabolic side effects. Some recently introduced new drugs (such as amisulpride, lurasidone, lumateperone, aripriprozole, brexpiprazole and cariprazine) have least liability of causing EPS but with mild side effect on weight gain (less than 1 kg during the treatment course for an episode of acute exacerbation in patients with schizophrenia). But patients’ cognitive improvement from drugs for treating patients with schizophrenia and comorbid depressive symptom are still often overlooked. Conclusion: Clinicians prescribe drugs with minimal EPS and mild weight gain for patients with schizophrenia, and pay attention to minimalize patients’ cognitive impairment and to treat comorbid depression. Then, patients with schizophrenia can expand new better potentials and opportunities for occupational rehabilitation. |
|||||||
| 言語 | en | |||||||
| 書誌情報 |
en : COGNITION & REHABILITATION 巻 3, 号 1, p. 52-58, 発行日 2022-11-30 |
|||||||
| 出版者 | ||||||||
| 出版者 | Osaka Kawasaki Rehabilitation University | |||||||
| 言語 | en | |||||||
| ISSN | ||||||||
| 収録物識別子タイプ | PISSN | |||||||
| 収録物識別子 | 2436-1097 | |||||||
